Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 51

1.

Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy.

Andersen S, Tarnow L, Rossing P, Hansen BV, Parving HH.

Kidney Int. 2000 Feb;57(2):601-6.

2.
3.

[The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].

Bernadet-Monrozies P, Rostaing L, Kamar N, Durand D.

Presse Med. 2002 Nov 9;31(36):1714-20. Review. French.

PMID:
12467154
4.

Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points.

Parving HH, Andersen S, Jacobsen P, Christensen PK, Rossing K, Hovind P, Rossing P, Tarnow L.

Semin Nephrol. 2004 Mar;24(2):147-57. Review.

PMID:
15017527
5.
6.

The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies.

Zanella MT, Ribeiro AB.

Clin Ther. 2002 Jul;24(7):1019-34. Review.

PMID:
12182249
7.

[Angiotensin II type-1 receptor antagonists and diabetes mellitus].

Schnack C, Schernthaner G.

Wien Med Wochenschr. 2001;151(7-8):165-8. Review. German.

PMID:
11450165
9.

Angiotensin receptor antagonists in patients with nephropathy due to type 2 diabetes.

Eberhard R, Dikow R.

Ann Med. 2002;34(7-8):507-13. Review.

PMID:
12553490
10.
11.

[Angiotensin II type-1-receptor antagonists from the viewpoint of nephrology].

Hauser AC, Hörl WH.

Wien Med Wochenschr. 2001;151(7-8):160-4. Review. German.

PMID:
11450164
12.

Losartan in diabetic nephropathy.

Perico N, Ruggenenti P, Remuzzi G.

Expert Rev Cardiovasc Ther. 2004 Jul;2(4):473-83. Review.

PMID:
15225108
13.

Prevention of loss of renal function over time in patients with diabetic nephropathy.

Barnett A.

Am J Med. 2006 May;119(5 Suppl 1):S40-7. Review.

PMID:
16563947
14.

Recommendations for the management of special populations: renal disease in diabetes.

Raij L.

Am J Hypertens. 2003 Nov;16(11 Pt 2):46S-49S. Review.

PMID:
14625161
15.

The RAAS in the pathogenesis and treatment of diabetic nephropathy.

Ruggenenti P, Cravedi P, Remuzzi G.

Nat Rev Nephrol. 2010 Jun;6(6):319-30. doi: 10.1038/nrneph.2010.58. Epub 2010 May 4. Review.

PMID:
20440277
16.

Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis.

Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, MacAllister RJ.

Lancet. 2005 Dec 10;366(9502):2026-33. Review.

PMID:
16338452
17.

Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: results from the AMADEO study.

Bichu P, Nistala R, Khan A, Sowers JR, Whaley-Connell A.

Vasc Health Risk Manag. 2009;5(1):129-40. Epub 2009 Apr 8. Review.

18.

Outcome studies in diabetic nephropathy.

Mohanram A, Toto RD.

Semin Nephrol. 2003 May;23(3):255-71. Review.

PMID:
12838494
19.

Angiotensin receptor blockers in diabetic nephropathy.

Price DA, Hollenberg NK.

Curr Diab Rep. 2001 Dec;1(3):267-74. Review.

PMID:
12643209
20.

Renal effects of angiotensin II receptor blockade in normotensive subjects.

Burnier M, Roch-Ramel F, Brunner HR.

Kidney Int. 1996 Jun;49(6):1787-90. Review.

Supplemental Content

Support Center